Lonza to Expand Viral Therapy Business with Planned Construction of New Facility in Houston, TX

19-Jun-2015 - USA

Lonza announced the planned expansion of its industry-leading viral gene therapy business. Lonza plans to construct a new 100,000 square foot facility for viral and immunotherapy development and manufacturing in the Houston, TX (USA) area, complete with a fully segregated fill/finish suite. This new facility will more than double Lonza’s capacity for the production of viral gene and virally modified therapeutics.

The state-of-the-art multi-purpose facility is expected to come on-line in the first half of 2017 and will include eight independent cGMP modular cleanrooms for 2,000 L-scale production in single-use bioreactors. Grade-B cleanrooms will also be constructed to continue the manufacture of EMA-regulated cell therapy products. The site master plan includes expanded process development and quality-control areas, shell space for future additional cleanrooms, and land for further potential expansions.

“The clinical landscape for targeted gene therapies continues to grow at a steady rate with new advancements in cancer immunotherapies and cardiovascular disease,” said Andreas Weiler, Ph.D, Head of Emerging Technologies for Lonza’s Pharma&Biotech segment. “This investment will allow Lonza to be well positioned to meet the demands of this growing market and to remain at the forefront of the viral gene therapy industry. Our viral team has more than 20 years of experience in viral vector gene therapy that, when combined with our newly constructed leading edge facility, will provide a key advantage to our customers and ultimately to their patients.
 

Other news from the department manufacturing

These products might interest you

Biostat STR

Biostat STR by Sartorius

Biostat STR Generation 3 Bioreactors

Engineered for Ultimate Upstream Performance

bioreactors
Ambr® 250 Modular

Ambr® 250 Modular by Sartorius

Mini bioreactors for cell and gene therapies with high scalability

Maximise your process development with reliable single-use vessels

bioreactors
Ambr® 250 HT Consumables

Ambr® 250 HT Consumables by Sartorius

Efficient bioprocesses with single-use bioreactors

Minimise cleaning effort and maximise flexibility for cell and microbial cultures

bioreactors
Flexcell Systems

Flexcell Systems by Dunn

Flexcell Cell Stretching Bioreactors for Life Science Research

Used in over 1300 laboratories worldwide, and cited in over 4000 research publications

bioreactors
Brooks Instrument SLA Biotech-Serie

Brooks Instrument SLA Biotech-Serie by Brooks Instrument

Control bioprocesses efficiently and precisely with flow controllers for biotechnology applications

The SLA Biotech series has been developed specifically for the requirements in bioprocesses

mass flow controllers
SLAMf Biotech-Serie Massendurchflussregler

SLAMf Biotech-Serie Massendurchflussregler by Brooks Instrument

SLAMf Mass Flow Controllers Designed Specifically for Biotech (IP66 / NEMA 4X)

Special equipment for biotech process plants, suitable for splash water and high-pressure cleaning

mass flow controllers
Loading...

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Gene therapy

Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.

View topic world
Topic world Gene therapy

Topic world Gene therapy

Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.